SkinBioTherapeutics PLC Notice of Investor Meet Company Presentation
October 04 2024 - 9:02AM
RNS Regulatory News
RNS Number : 0460H
SkinBioTherapeutics PLC
04 October 2024
SkinBioTherapeutics
plc
("SkinBioTherapeutics" or "the Company")
Notice of Investor Meet
Company presentation
4
October 2024 - SkinBioTherapeutics
plc (AIM: SBTX), a
life science company focused on skin health, will be giving an
update to investors on Friday 11 October 2024 via the Investor Meet
Company platform.
The presentation will take place at
10am (BST) via this link
HERE. Questions can be submitted
pre-event via the Investor
Meet Company dashboard up
to the day before the meeting or at any time during the
presentation.
Investors who already follow
SkinBioTherapeutics on the Investor Meet Company platform
will automatically be invited. Investors can sign up
to Investor Meet Company for free via
this link.
For
more information please contact:
|
SkinBioTherapeutics plc
Stuart J. Ashman, CEO
Manprit Randhawa, CFO
|
+44 (0) 191 495
7325
|
|
Cavendish Capital Markets Limited
(Nominated Adviser & Broker)
Giles Balleny, Dan Hodkinson
(Corporate Finance)
Charlie Combe (Broking)
Dale Bellis, Tamar Cranford-Smith
(Sales)
|
+44 (0) 20 7220
0500
|
|
Vigo
Consulting (financial press)
Rozi Morris
|
+44 (0) 20 7390
0230
SkinBio@vigoconsulting.com
|
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life
science company focused on skin health. The Company's proprietary
platform technology, SkinBiotix®, is based upon discoveries made by
the translational dermatology team at the University of
Manchester.
The Company is targeting a number of
skin healthcare sectors, the most advanced of which are cosmetic
skincare and food supplements to modulate the immune system by
harnessing the gut-skin axis. In each area SkinBioTherapeutics
plans to exemplify its technology through human studies. The
Company's first product, AxisBiotix-Ps™, a food supplement to
address the symptoms of mild to moderate psoriasis.
The Company listed on AIM in April
2017 and is based in Newcastle, UK. For more information,
visit: www.skinbiotherapeutics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
MSCFSUFELELSEIS
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Oct 2024 to Nov 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Nov 2023 to Nov 2024
